{
    "2021-06-26": [
        [
            {
                "time": "2023-10-15",
                "original_text": "Investigational 2.0 mg dose of Ozempic® (semaglutide) demonstrates superior reductions in blood sugar vs Ozempic® 1.0 mg in adults with type 2 diabetes in a phase 3 trial",
                "features": {
                    "keywords": [
                        "Ozempic",
                        "semaglutide",
                        "superior reductions",
                        "blood sugar",
                        "type 2 diabetes",
                        "phase 3 trial"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}